13F-HR filed by Hillview Capital Advisors, LLC
Hillview Capital Advisors, LLC filed this 13F-HR for the quarter ended 2018-09-30, filed 2018-10-23, with 5 holding rows worth $25,866,000.
- Accession
- 0001172661-18-001881
- Filer
- CIK 1631615
- Filed
- 2018-10-23
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2018
A combination report, 5 entries on the cover page, a total value of $25,866,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $25,866,000 with VALUE read as thousands by filing date, 13F file number 028-16536. The quarter's positions are built on this report. The resolved quarter.
Other managers
- reports for this filerADVISOR PARTNERS LLC028-13399
- reports for this filerCopeland Capital Management, LLC028-14668
- reports for this filerRelative Value Partners, LLC028-12229
- reports for this filerTORTOISE CAPITAL ADVISORS, L.L.C.028-11123
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| Vanguard FTSE Developed Markets ETF | 921943858 | SHS | 449,622 | $19,455,000 | thousands by filing date | |
| Vanguard Total World Stock ETF | 922042742 | SHS | 76,983 | $5,838,000 | thousands by filing date | |
| Amazon.com, Inc | 023135106 | COM | 113 | $226,000 | thousands by filing date | |
| Vanguard Dividend Appreciation ETF | 921908844 | SHS | 1,919 | $213,000 | thousands by filing date | |
| INNOVATE BIOPHARMACEUTICLS I | 45782F105 | COM PAR | 19,610 | $134,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001172661-18-001881 | this filing | 2018-10-23 | acceptance time not in the bulk data set |